Home › Lymphoma › Minnesota
Lymphoma clinical trials in Minnesota
14 studies for Lymphoma are looking for participants at sites in Minnesota.
Cities in Minnesota
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT03418038CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- University of Minnesota/Masonic Cancer Center, Minneapolis
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Rochester
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingEarly phase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Mar 16, 2026 · NCT05294367BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT06854003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Fairview Southdale Hospital, Edina
- Hennepin County Medical Center, Minneapolis
- Monticello Cancer Center, Monticello
- and 5 more
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jan 13, 2026 · NCT05006482WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Oct 15, 2025 · NCT07058064From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.